Regulation 7

in item 7, in paragraph (a), after sub‑paragraph (x), insert — “(xa)Category 11 $2,200 per month”;

in item 7, in paragraph (a), replace sub‑paragraph (xia) with — “(xia)Category 14 $2,800 per month”;

in item 7, in paragraph (a), replace sub‑paragraphs (xiv), (xv), (xvi), (xvia), (xvii) and (xviii) with — “(xiv)Category 18 $3,600 per month (xv)Category 21 $4,200 per month (xvi)Category 22 $4,400 per month (xvii)Category 23 $4,600 per month (xviii)Category 25 $5,000 per month (xix)Category 33 $6,600 per month (xx)Category 34 $6,800 per month (xxi)Category 51 $10,200 per month (xxii)Category 62 $12,400 per month (xxiii)Category 64 $12,800 per month”;

replace items 7B and 7C with — “7B.Any one or both of the following treatments:

Cancer drug treatment (excluding the cost of any cancer drug administered) for only one neoplasm, received as outpatient medical treatment, where treatment is received on or after 1 January 2023 but before 1 June 2026;

CTGTP treatment (excluding the cost of any CTGTP administered) for only one neoplasm, received as outpatient medical treatment, where treatment is received on or after 1 October 2025 but before 1 June 2026 $3,600 per year 7C.Any one or both of the following treatments:

Cancer drug treatment (excluding the cost of any cancer drug administered) for multiple neoplasms concurrently, received as outpatient medical treatment, where treatment is received on or after 1 December 2023 but before 1 June 2026; $7,200 per year (b)CTGTP treatment (excluding the cost of any CTGTP administered) for multiple neoplasms concurrently, received as outpatient medical treatment, where treatment is received on or after 1 October 2025 but before 1 June 2026 7D.Any one or both of the following treatments:

Cancer drug treatment (excluding the cost of any cancer drug administered) for only one neoplasm, received as outpatient medical treatment, where treatment is received on or after 1 June 2026;

CTGTP treatment (excluding the cost of any CTGTP administered) for only one neoplasm, received as outpatient medical treatment, where treatment is received on or after 1 June 2026 $4,500 per year 7E.Any one or both of the following treatments:

Cancer drug treatment (excluding the cost of any cancer drug administered) for multiple neoplasms concurrently, received as outpatient medical treatment, where treatment is received on or after 1 June 2026; $9,000 per year”; (b)CTGTP treatment (excluding the cost of any CTGTP administered) for multiple neoplasms concurrently, received as outpatient medical treatment, where treatment is received on or after 1 June 2026 (e)in item 11B, in the first column, after “1 April 2025”, insert “but before 1 June 2026”;

after item 11B, insert — “11C.Radiosurgery treatment, received as outpatient medical treatment on or after 1 June 2026 $15,700 per course of treatment”;

in item 13, in the first column, after “1 April 2019”, insert “but before 1 June 2026”;

after item 13, insert — “13A.Autologous bone marrow transplant for the treatment of multiple myeloma, received as outpatient medical treatment on or after 1 June 2026 $6,000 per treatment”; and

in item 19, in the second column, replace “for 39 treatment sessions in an insured person’s lifetime” with “subject to maximum number of treatment sessions the insured person is entitled to claim under regulation 13(3A)”.